Telix Pharmaceuticals is entering into a collaboration with Merck for research studies on the combination of Merck's DNA damage response inhibitor (DDRi) molecules with Telix's therapeutic radiotracers.
The studies will investigate the combination of Merck's DDRi molecules with Telix's TLX591 (lutetium-177 rosopatamab) and TLX250 (lutetium-177 girentuximab) molecularly targeted radiation therapeutic programs for prostate and renal cancers, respectively.
This clinical collaboration builds on a strategic research collaboration agreement between Telix and Merck announced in August 2019.
Under the terms of the collaboration, Telix and Merck will investigate the synergy of these products with Merck's DDRi compound across a variety of oncology indications in clinical settings.
